alendronate has been researched along with Cystic Fibrosis in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo." | 6.73 | Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). ( Adachi, JD; Berthiaume, Y; Freitag, A; Ioannidis, G; Jeanneret, A; Kennedy, CC; Matouk, E; Nixon, M; O'Neill, J; Papaioannou, A; Paterson, N; Pui, M; Rabin, HR; Villeneuve, J; Webber, C, 2008) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 6.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis." | 3.01 | Bisphosphonates for osteoporosis in people with cystic fibrosis. ( Chang, AB; Conwell, LS; Jeffery, TC, 2023) |
| "Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo." | 2.73 | Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). ( Adachi, JD; Berthiaume, Y; Freitag, A; Ioannidis, G; Jeanneret, A; Kennedy, CC; Matouk, E; Nixon, M; O'Neill, J; Papaioannou, A; Paterson, N; Pui, M; Rabin, HR; Villeneuve, J; Webber, C, 2008) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 2.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jeffery, TC | 1 |
| Chang, AB | 1 |
| Conwell, LS | 1 |
| Le Henaff, C | 1 |
| Velard, F | 1 |
| Jacquot, J | 1 |
| Bianchi, ML | 1 |
| Colombo, C | 1 |
| Assael, BM | 1 |
| Dubini, A | 1 |
| Lombardo, M | 1 |
| Quattrucci, S | 1 |
| Bella, S | 1 |
| Collura, M | 1 |
| Messore, B | 1 |
| Raia, V | 1 |
| Poli, F | 1 |
| Bini, R | 1 |
| Albanese, CV | 1 |
| De Rose, V | 1 |
| Costantini, D | 1 |
| Romano, G | 1 |
| Pustorino, E | 1 |
| Magazzù, G | 1 |
| Bertasi, S | 1 |
| Lucidi, V | 1 |
| Traverso, G | 1 |
| Coruzzo, A | 1 |
| Grzejdziak, AD | 1 |
| Papaioannou, A | 1 |
| Kennedy, CC | 1 |
| Freitag, A | 1 |
| Ioannidis, G | 1 |
| O'Neill, J | 1 |
| Webber, C | 1 |
| Pui, M | 1 |
| Berthiaume, Y | 1 |
| Rabin, HR | 1 |
| Paterson, N | 1 |
| Jeanneret, A | 1 |
| Matouk, E | 1 |
| Villeneuve, J | 1 |
| Nixon, M | 1 |
| Adachi, JD | 1 |
| Aris, RM | 1 |
| Lester, GE | 1 |
| Caminiti, M | 1 |
| Blackwood, AD | 1 |
| Hensler, M | 1 |
| Lark, RK | 1 |
| Hecker, TM | 1 |
| Renner, JB | 1 |
| Guillen, U | 1 |
| Brown, SA | 1 |
| Neuringer, IP | 1 |
| Chalermskulrat, W | 1 |
| Ontjes, DA | 1 |
| Girón, RM | 1 |
| Sánchez Moliní, P | 1 |
| García Vadillo, A | 1 |
| Quintana, ML | 1 |
| Rodríguez Salvanés, F | 1 |
| Jiménez, I | 1 |
| Mancha, A | 1 |
| Cisneros, C | 1 |
| Ancochea, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients[NCT00157690] | Phase 4 | 56 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Cystic Fibrosis
| Article | Year |
|---|---|
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female | 2023 |
3 trials available for alendronate and Cystic Fibrosis
| Article | Year |
|---|---|
Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Biomarkers; Bone Density; Bone Density Conservation | 2013 |
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Co | 2008 |
Efficacy of alendronate in adults with cystic fibrosis with low bone density.
Topics: Administration, Oral; Adult; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Cysti | 2004 |
2 other studies available for alendronate and Cystic Fibrosis
| Article | Year |
|---|---|
Bone health in cystic fibrosis: use of oral bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcifediol; Calcium; Cystic Fibrosis; | 2013 |
[Protocol for prevention and treatment of osteoporosis in patients with cystic fibrosis].
Topics: Adult; Alendronate; Bone Density; Calcium Compounds; Clinical Protocols; Cystic Fibrosis; Dietary Su | 2005 |